Redeye provides its initial take on MedCap’s Q1 2025 report, which broadly aligned with our estimates. We judge that positives from the report include strong growth and solid margins for business area Assistive Tech. Notable negatives include continued weakness in business area Specialty Pharma.
LÄS MER
